Phase II study with pharmacodynamic evaluation of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC)

被引：0
|
作者：
Fontana, A. [1 ]
Galli, L. [2 ]
Derosa, L. [2 ]
Minuti, G. [2 ]
D'Arcangelo, M. [2 ]
Bursi, S. [2 ]
Landi, L. [2 ]
Bocci, G. [3 ]
Santini, D. [4 ]
Falcone, A. [3 ]
机构：
[1] Azienda Osped Univ Pisana, Pisa, Italy
[2] ASL6 Livorno, Med Oncol, Livorno, Italy
[3] Univ Pisa, Pisa, Italy
[4] Univ Campus Biomed, Rome, Italy
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71414-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：417 / 417
页数：1
相关论文
共 50 条
  • [21] A PHASE I STUDY OF ORAL PANOBINOSTAT (LBH589) ALONE AND IN COMBINATION WITH DOCETAXEL (DOC) AND PREDNISONE IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
    Rathkopf, D. E.
    Wong, B. Y.
    Ross, R. W.
    George, D. J.
    Picus, J.
    Atadja, P.
    Yang, W.
    Culver, K. W.
    Woo, M. M.
    Scher, H. I.
    ANNALS OF ONCOLOGY, 2008, 19 : 199 - 200
  • [22] A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (CRPC)
    Rathkopf, D. E.
    Wong, B. Y.
    Ross, R. W.
    George, D. J.
    Picus, J.
    Tanaka, E.
    Chen, Y.
    Atadja, P.
    Yang, W.
    Culver, K. W.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [23] A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC)
    Sonpavde, G.
    Matveev, V. B.
    Burke, J. M.
    Caton, J. R.
    Fleming, M. T.
    Karlov, P. A.
    Holmlund, J.
    Wood, B. A.
    Brookes, M.
    Leopold, L. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [24] A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT-101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC)
    Sonpavde, G.
    Matveev, V. B.
    Burke, J. M.
    Caton, J. R.
    Fleming, M. T.
    Karlov, P. A.
    Holmlund, J.
    Wood, B. A.
    Brookes, M.
    Leopold, L. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Docetaxel and curcuminoids combination in patients with castration-resistant prostate cancer: A phase II study
    Mahammedi, H.
    Pouget, M.
    Planchat, E.
    Cure, H.
    Durando, X.
    Van-Praagh, I.
    Savareux, L.
    Abrial, C.
    Chollet, P.
    Eymard, J. C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S696 - S696
  • [26] A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C plus DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).
    Al Harthy, Munjid
    Madan, Ravi Amrit
    Karzai, Fatima
    Petrylak, Daniel Peter
    Kim, Joseph W.
    Arlen, Philip M.
    Theoret, Marc Robert
    Marte, Jenn
    Bilusic, Marijo
    Couvillon, Anna
    Chun, Guinevere
    Owens, Helen
    Hankin, Amy
    Cordes, Lisa M.
    Figg, William Douglas
    Gulley, James L.
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [27] Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial
    Caffo, Orazio
    Ortega, Cinzia
    Nole, Franco
    Gasparro, Donatello
    Mucciarini, Claudia
    Aieta, Michele
    Zagonel, Vittorina
    Iacovelli, Roberto
    De Giorgi, Ugo
    Facchini, Gaetano
    Veccia, Antonello
    Palesandro, Erica
    Verri, Elena
    Buti, Sebastiano
    Razzini, Giorgia
    Bozza, Giovanni
    Maruzzo, Marco
    Ciccarese, Chiara
    Schepisi, Giuseppe
    Rossetti, Sabrina
    Maines, Francesca
    Kinspergher, Stefania
    Fratino, Lucia
    Ermacora, Paola
    Nicodemo, Maurizio
    Giordano, Monica
    Sartori, Donata
    Scapoli, Daniela
    Sabbatini, Roberto
    Lo Re, Giovanni
    Morelli, Franco
    D'Angelo, Alessandro
    Vittimberga, Isabella
    Lippe, Paolo
    Carrozza, Francesco
    Messina, Caterina
    Galli, Luca
    Valcamonico, Francesca
    Porta, Camillo
    Pappagallo, Giovanni
    Aglietta, Massimo
    EUROPEAN JOURNAL OF CANCER, 2021, 155 : 56 - 63
  • [28] A Randomised Phase II Trial Comparing Docetaxel Plus Prednisone with Docetaxel Plus Prednisone Plus Low-Dose Cyclophosphamide in Castration-Resistant Prostate Cancer
    Porsch, Markus
    Ulrich, Matthias
    Wendler, Johann Jakob
    Liehr, Uwe-Bernd
    Reiher, Frank
    Janitzky, Andreas
    Baumunk, Daniel
    Schindele, Daniel
    Seseke, Florian
    Lux, Anke
    Schostak, Martin
    CHEMOTHERAPY, 2014, 60 (02) : 129 - 134
  • [29] Phase II clinical trial of metronomic cyclophosphamide (CTX) plus celecoxib (C) and dexamethasone (DEX) in advanced hormone refractory prostate cancer (HRPC): preliminary clinical and pharmacodynamic results
    Fontana, A.
    Bocci, G.
    Galli, L.
    Fontana, E.
    Galli, C.
    Landi, L.
    Fioravanti, A.
    Di Marsico, R.
    Del Tacca, M.
    Facone, A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 288 - 288
  • [30] Phase II clinical trial of metronomic cyclophosphamide (CTX) plus celecoxib (C) and dexamethasone (DEX) in advanced hormone refractory prostate cancer (HRPC): Preliminary clinical and pharmacodynamic results
    Fontana, A.
    Bocci, G.
    D'Arcangelo, M.
    Galli, L.
    Fontana, E.
    Galli, C.
    Landi, L.
    Fioravanti, A.
    Orlandi, P.
    Barletta, M.
    Marsico, R.
    Barsanti, G.
    Andreuccetti, M.
    Del, Tacca M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 82 - 82
12345